Wendtner, Clemens-Martin (2019). Ibrutinib: the home run for cure in CLL? Blood, 133 (19). S. 2003 - 2005. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Full text not available from this repository.Abstract
In this issue of Blood, Byrd et al report that after nearly 4 years of follow-up, there is an impressive and sustained progression-free survival and overall survival benefit to using the Bruton's tyrosine kinase inhibitor ibrutinib vs ofatumumab in patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). Nevertheless, patients with specific high-risk features like TP53 or SF3B1 mutations showed a trend toward shorter progression-free survival, and altogether, only half of the enrolled patients were still receiving ibrutinib at the end of the observation period. 1
| Item Type: | Journal Article | ||||||||
| Creators: |
|
||||||||
| URN: | urn:nbn:de:hbz:38-148390 | ||||||||
| DOI: | 10.1182/blood-2019-03-901090 | ||||||||
| Journal or Publication Title: | Blood | ||||||||
| Volume: | 133 | ||||||||
| Number: | 19 | ||||||||
| Page Range: | S. 2003 - 2005 | ||||||||
| Date: | 2019 | ||||||||
| Publisher: | AMER SOC HEMATOLOGY | ||||||||
| Place of Publication: | WASHINGTON | ||||||||
| ISSN: | 1528-0020 | ||||||||
| Language: | English | ||||||||
| Faculty: | Unspecified | ||||||||
| Divisions: | Unspecified | ||||||||
| Subjects: | no entry | ||||||||
| Uncontrolled Keywords: |
|
||||||||
| Refereed: | Yes | ||||||||
| URI: | http://kups.ub.uni-koeln.de/id/eprint/14839 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
 |
View Item |